Valneva SE (0OB3.L)
EUR 3.02
(0.8%)
EUR 3.02
(0.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -101.42 Million EUR | 29.21% |
| 2022 | -143.27 Million EUR | -95.14% |
| 2021 | -73.42 Million EUR | -14.03% |
| 2020 | -64.39 Million EUR | -3592.26% |
| 2019 | -1.74 Million EUR | -153.43% |
| 2018 | 3.26 Million EUR | 128.43% |
| 2017 | -11.48 Million EUR | 76.66% |
| 2016 | -49.18 Million EUR | -138.56% |
| 2015 | -20.61 Million EUR | 21.52% |
| 2014 | -26.27 Million EUR | -8.97% |
| 2013 | -24.11 Million EUR | -62.46% |
| 2012 | -14.84 Million EUR | -235.85% |
| 2011 | -4.41 Million EUR | 44.5% |
| 2010 | -7.96 Million EUR | -29.59% |
| 2009 | -6.14 Million EUR | -157.18% |
| 2008 | -2.38 Million EUR | 28.94% |
| 2007 | -3.36 Million EUR | -1283.54% |
| 2006 | -243 Thousand EUR | 80.08% |
| 2005 | -1.22 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 58.9 Million EUR | 283.19% |
| 2024 Q2 | -24.93 Million EUR | -142.32% |
| 2023 Q3 | -34.22 Million EUR | -102.29% |
| 2023 Q1 | -18.12 Million EUR | 58.99% |
| 2023 Q4 | -32.15 Million EUR | 6.04% |
| 2023 Q2 | -16.91 Million EUR | 6.66% |
| 2023 FY | -101.42 Million EUR | 29.21% |
| 2022 Q2 | -145.45 Million EUR | -458.55% |
| 2022 FY | -143.27 Million EUR | -95.14% |
| 2022 Q4 | -44.2 Million EUR | -161.04% |
| 2022 Q3 | 72.41 Million EUR | 149.79% |
| 2022 Q1 | -26.04 Million EUR | -115.1% |
| 2021 Q2 | -58.69 Million EUR | -111.89% |
| 2021 Q1 | -27.7 Million EUR | -1245.41% |
| 2021 FY | -73.42 Million EUR | -14.03% |
| 2021 Q3 | -159.53 Million EUR | -171.79% |
| 2021 Q4 | 172.5 Million EUR | 208.13% |
| 2020 Q3 | -36.69 Million EUR | -50.33% |
| 2020 FY | -64.39 Million EUR | -3592.26% |
| 2020 Q2 | -24.41 Million EUR | -1886.17% |
| 2020 Q1 | -1.22 Million EUR | -278.12% |
| 2020 Q4 | -2.05 Million EUR | 94.39% |
| 2019 Q2 | -7.25 Million EUR | -249.47% |
| 2019 FY | -1.74 Million EUR | -153.43% |
| 2019 Q4 | 690 Thousand EUR | 2190.91% |
| 2019 Q3 | -33 Thousand EUR | 99.55% |
| 2019 Q1 | 4.85 Million EUR | -25.53% |
| 2018 Q2 | -1.65 Million EUR | -213.31% |
| 2018 Q1 | 1.45 Million EUR | 139.64% |
| 2018 FY | 3.26 Million EUR | 128.43% |
| 2018 Q4 | 6.51 Million EUR | 312.97% |
| 2018 Q3 | -3.06 Million EUR | -85.23% |
| 2017 Q2 | -2.7 Million EUR | -63.25% |
| 2017 Q4 | -3.67 Million EUR | -6.86% |
| 2017 Q3 | -3.44 Million EUR | -27.25% |
| 2017 FY | -11.48 Million EUR | 76.66% |
| 2017 Q1 | -1.65 Million EUR | 39.01% |
| 2016 Q4 | -2.71 Million EUR | 61.22% |
| 2016 FY | -49.18 Million EUR | -138.56% |
| 2016 Q3 | -7 Million EUR | 79.64% |
| 2016 Q2 | -34.42 Million EUR | -583.38% |
| 2016 Q1 | -5.03 Million EUR | -546.6% |
| 2015 Q2 | -8.97 Million EUR | -78.72% |
| 2015 Q1 | -5.01 Million EUR | 56.43% |
| 2015 FY | -20.61 Million EUR | 21.52% |
| 2015 Q4 | -779 Thousand EUR | 86.68% |
| 2015 Q3 | -5.85 Million EUR | 34.78% |
| 2014 Q3 | -2.56 Million EUR | 49.36% |
| 2014 FY | -26.27 Million EUR | -8.97% |
| 2014 Q1 | -7.11 Million EUR | -17.98% |
| 2014 Q2 | -5.07 Million EUR | 28.7% |
| 2014 Q4 | -11.52 Million EUR | -348.6% |
| 2013 Q3 | -9.96 Million EUR | -79.12% |
| 2013 Q4 | -6.02 Million EUR | 39.53% |
| 2013 FY | -24.11 Million EUR | -62.46% |
| 2013 Q1 | -2.54 Million EUR | 48.09% |
| 2013 Q2 | -5.56 Million EUR | -118.32% |
| 2012 Q3 | -2.42 Million EUR | 0.0% |
| 2012 Q4 | -4.91 Million EUR | -102.22% |
| 2012 FY | -14.84 Million EUR | -235.85% |
| 2011 FY | -4.41 Million EUR | 44.5% |
| 2010 FY | -7.96 Million EUR | -29.59% |
| 2009 FY | -6.14 Million EUR | -157.18% |
| 2008 FY | -2.38 Million EUR | 28.94% |
| 2007 FY | -3.36 Million EUR | -1283.54% |
| 2006 FY | -243 Thousand EUR | 80.08% |
| 2005 FY | -1.22 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Boiron SA | 35.82 Million EUR | 383.108% |
| Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 159.547% |
| Vetoquinol SA | 55.56 Million EUR | 282.558% |
| AB Science S.A. | -10.04 Million EUR | -909.445% |
| Nanobiotix S.A. | -39.7 Million EUR | -155.489% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | -331.833% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -257.875% |
| BioSenic S.A. | -28.77 Million EUR | -252.453% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 31.346% |
| Formycon AG | 75.79 Million EUR | 233.82% |